Entrant ICD and CRT-D Ordering Information | Abbott
CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D) EntrantTM HF CRT-D CDHFA300B HF Smartphone Connectivity MR Compatible with myMerlinPulseTM app Product Highlights · Bluetooth® Low Energy (LE) communication enabling Smartphone Connectivity through data encryption. · SyncAVTM CRT technology offers dynamic AV timing with customizable programming to ensure BiV pacing. · Cold can programmability provides an additional RV-SVC shock configuration to decouple the can from the shocking vector parameters in cases of lead problems. · DeFT ResponseTM Technology offers noninvasive programming options to optimize rescue therapy to each patient's unique physiology and changing conditions. · VF Therapy Assurance decreases time to treatment for arrhythmias in patients who are likely to be hemodynamically unstable. · Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone further extends the programming options for terminating tachyarrhythmias without a highvoltage shock. · ShockGuardTM technology with DecisionTxTM programming designed to reduce inappropriate therapy and minimize the need for programming adjustments at implant. SecureSenseTM RV lead noise discrimination detects sustained lead noise and short bursts of oversensing that would otherwise go unnoticed or potentially lead to one or more inappropriate shocks. Far Field MDTM morphology discrimination and Chamber Onset discrimination enhance SVT and VT discrimination for reduced inappropriate therapies. · SenseAbilityTM sensing algorithm feature provides the flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity. · DynamicTxTM over-current detection algorithm automatically changes shock configurations to ensure delivery of highvoltage therapy when high current is detected. · MRI-Ready device tested in combination with MR Conditional leads for full-body scans using a 1.5T or 3T (Tesla) field strength MRI Scanner*. · Premature Atrial Contraction (PAC) Response to avoid pacing the atrium in a vulnerable zone. · Physiologic rate responsive AV Delay and PVARP. · QuickOptTM timing cycle optimization provides quick and effective optimization at the push of a button. · Dual patient notification: audio notification through the device and visual notification via myMerlinPulseTM app. · The CorVueTM thoracic impedance feature measures transthoracic impedance changes over time to provide additional insight into the patient's heart failure condition. Ordering Information Contents: Cardiac Pulse Generator MODEL NUMBER DIMENSIONS (L × W × H) (MM) WEIGHT (G) VOLUME (CC) CONNECTOR DEFIBRILLATION CONNECTOR SENSE/PACE CDHFA300B 79 × 51 × 12 *See MRI Scan Parameters in MRI-Ready Systems Manual. 74 37 DF-1 IS-1 CONNECTOR PACE - LEFT VENTRICLE IS-1 EntrantTM HF CDHFA300B CRT-D DEVICE Product Specifications PARAMETER SPECIFICATIONS Model Telemetry Delivered/Stored Energy Volume Weight Size Defibrillation Lead Connection Atrial Sense/Pace Lead Connection Ventricular Sense/Pace Lead Connection Left Ventricular Pace Lead Connection High Voltage Can Parameter Biventricular Pacing V. Triggering V-V Timing Interventricular Pace Delay Ventricular Sensing Ventricular Pacing Chamber SyncAVTM CRT Technology Delta Sensing/Detection SenseAbilityTM Sensing Algorithm Low Frequency Attenuation Threshold Start Decay Delay Ventricular Sense Refractory Detection Zones SVT Discriminators Monitor Mode Discrimination Modes CDHFA300B Bluetooth® LE Communication 36/39 J 37 cc 74 g 79 × 51 × 12 mm DF-1 IS-1 in-line bipolar IS-1 in-line bipolar IS-1 Electrically active titanium can Settings On; Off Simultaneous; RV First; LV First RV First 10-80/LV First 15-80 ms RV only (not programmable) RV only; Biventricular -10 to -120 ms; Off Automatic sensitivity control adjustment for atrial and ventricular events On; Off Post-Sensed: 50; 62.5; 75; 100%; Post-Paced; Atrial: 0.2-3.0 mV Post-Paced; Ventricular: Auto: 0.2-3.0 mV Post-Sensed: 0-220 ms Post-Paced; Atrial: 0-220 ms Post-Paced; Ventricular: Auto; 0-220 ms 125; 157 ms 3 zone programming - 1 zone; 2 zones or 3 zones (VT-1; VT-2; VF) AV Rate Branch; Arrhythmia Onset (Chamber Onset or Sudden Onset); Interval Stability; AV Association Morphology; Discrimination (Far Field MDTM Morphology Discrimination or Original MD) with Automatic Template Update Detection; discrimination and diagnostics; no therapy delivery (VT or VT-1 zone) On; Passive; Off EntrantTM HF CDHFA300B CRT-D DEVICE Product Specifications Parameter Sensing/Detection SVT Upper Limit SVT Discrimination Timeout Reconfirmation SecureSenseTM RV Lead Noise Discrimination Algorithm VF Therapy Assurance Antitachycardia Pacing Therapy ATP Configurations ATP in VF Zone ATP Upper Rate Cutoff Burst Cycle Length Min. Burst Cycle Length Readaptive Number of Bursts/Stimuli Add Stimuli per Burst ATP Pulse Amplitude ATP Pulse Width High-Voltage Therapy DynamicTxTM Over-Current Detection Algorithm DeFT ResponseTM Technology High-Voltage Output Mode Waveform RV Polarity Electrode Configuration Bradycardia Pacing Permanent Modes Temporary Modes Rate-Adaptive Sensor Programmable Rate and Delay Parameters Pulse Amplitude Pulse Width LVCapTM Confirm Feature RVCapTM Confirm Feature ACapTM Confirm Feature Auto Mode Switch (AMS) Atrial Tachycardia Detection Rate AMS Base Rate Auto PMT Detection/Termination Rate Responsive PVARP Rate Responsive V Pace Refractory PAC Response PAC Response Interval Shortest AV Delay Settings 150-240 bpm 20s-60 min; Off Continuous sensing during charging On; On with Timeout; Passive; Off On; Off Ramp; Burst; Scan; 1 or 2 schemes per VT zone ATP While Charging; ATP Prior to Charging; Off 150-300 bpm Adaptive (50%-100%); Fixed (200-550 ms) 150-400 in increments of 5 ms On; Off 1-15 with 2-20 Stimuli On; Off 7.5 V independent from Bradycardia and Post-Therapy Pacing 1.0 or 1.5 ms independently programmable from Bradycardia and Post-Therapy Pacing On; Off Programmable pulse width for P1/P2 and tilt Fixed Pulse Width; Fixed Tilt Biphasic; Monophasic Cathode (-); Anode (+) RV to Can; RV to SVC/Can; RV to SVC DDD(R); DDT(R); DDI(R); VVT(R); VVI(R); AAI(R); Off DDD; DDT; DDI; VVT; VVI; AAI; AAT; DOO; VOO; AOO; Off On; Off; Passive Off; Base Rate (bpm); Rest Rate (bpm); Maximum Tracking Rate (bpm); Max Trigger Rate (bpm) Maximum Sensor Rate (bpm); Paced AV Delay (ms); Sensed AV Delay (ms); Rate Responsive AV Delay; Hysteresis Rate (bpm); Rate Hysteresis with Search 0.25-7.5 V 0.05; 0.1-1.5 ms Setup; On; Monitor; Off Setup; On; Monitor; Off On; Monitor; Off DDI(R); DDT(R); VVI(R); VVT(R); Off 110-300 bpm 40; 45; ... 135 bpm Atrial Pace; Passive; Off Low; Medium; High; Off On; Off On; Off 200-400 ms 25-120 ms EntrantTM HF CDHFA300B CRT-D DEVICE Product Specifications Parameter Settings Post-Therapy Pacing (Independently programmable from Bradycardia and ATP) Post-Shock Pacing Mode AAI; VVI; DDI; or DDD; Off Post-Shock Base Rate 30-100 bpm Post-Shock Pacing Duration 0.5; 1; 2.5; 5; 7.5; or 10 min; Off Device Testing/Induction Methods DC FibberTM Induction Method Pulse Duration 0.5-5.0 sec BurstFibberCycle Length 20-100 ms Noninvasive Programmed Stimulation (NIPS) 2-25 stimuli with up to three extra stimuli Patient Notifiers Programmable Notifiers (On; Off) BatteryAssuranceTM alert; Possible HV circuit damage; HV charge timeout; Long charge time for Capacitor Maintenance; Device at ERI; Right ventricular pacing lead impedance out of range; Left ventricular lead impedance out of range; High-voltage lead impedance out of range; AT/AF episode duration; AT/AF Burden; High ventricular rate during AT/AF; SecureSenseTM lead noise detection; Non-sustained ventricular oversensing; Biventricular pacing percentage lower than limit Device Parameter Reset On Entry into Backup VVI Mode On Auditory Duration 2; 4; 6; 8; 10; 12; 14; 16 sec Number of Audio Alerts per Notification 2 Number of Notifications 1-16 Time Between Notifications 10; 22 hours Electrograms and Diagnostics Stored Electrograms Up to 15 minutes (2 user programmable + discrimination channel); up to one minute programmable pretrigger data per VT/VF electrograms; additional triggers include lead noise detection; non-sustained ventricular oversensing; morphology template updates; atrial episode; PMT termination; PAC response; magnet reversion; noise reversion Therapy Summary Diagram of therapies delivered Episodes Summary Directory listing of up to 60 episodes with access to more details including stored electrograms Lifetime Diagnostics History of bradycardia events and device-initiated charging AT/AF Burden Trend Trend data and counts Ventricular HV Lead Impedance Trend Multi-Vector Trend Data Histograms and Trends Event Histogram; AV Interval Histogram; Mode Switch or AT/AF Duration Histogram; Peak Filtered Atrial Rate Histogram; Atrial Heart Rate Histogram; Ventricular Heart Rate Histogram; AT/AF Burden; Exercise and Activity Trending; V Rates During AMS; DirectTrendTM reports up to 1 year PMT Data Information regarding PMT detections Real-Time Measurements (RTM) Pacing lead impedances; high-voltage lead impedances; and signal amplitudes CorVue Thoracic Impedance CorVue Thoracic Impedance MRI Settings On; Off Threshold 8-18 days Tachy Therapy Disabled MRI Mode DOO; VOO; AOO; Pacing Off MRI Base Rate 30-100 bpm MRI Paced AV Delay 25-110 ms MRI RA and RV Pulse Amplitude 5.0 or 7.5 V MRI RA and RV Pulse Width 1.0 ms MRI RA and RV Pulse Configuration Bipolar MRI V Pacing Chamber RV Only MRI Timeout 3; 6; 9; 12; 24 hours; Off EntrantTM HF CDHFA300B CRT-D DEVICE Product Specifications MRI SCAN PARAMETERS§ Lead Model DurataTM Defibrillation Lead 7120 (Lead lengths: 60, 65 cm) 7122 (Lead lengths: 60, 65 cm) OptisureTM Lead LDA220 (Lead lengths: 60, 65 cm) LDA210 (Lead lengths: 60, 65 cm) TendrilTM STS Pacing Lead 2088TC (Lead lengths: 46, 52, 58 cm) Tendril MRITM Pacing Lead LPA1200M (Lead lengths: 46, 52 cm) UltiPaceTM Pacing Lead LPA1231 (Lead lengths: 46, 52, 58, 65 cm) Magnet (Tesla) 1.5 T / 3 T 1.5 T / 3 T 1.5 T / 3 T 1.5 T 1.5 T / 3 T RF Transmit Conditions Scan Region Normal Operating Mode Full-body LV first with 10 ms interventricular delay. § For additional information about specific MR Conditional CRT-Ds and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI-Ready Systems Manual at medical.abbott/manuals. Rx Only Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Intended Use: The Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices are primarily intended for use with compatible leads to detect and treat life threatening ventricular arrhythmias by providing ventricular antitachycardia pacing and ventricular cardioversion/ defibrillation. In addition, these devices can detect and treat: chronic symptomatic bradyarrhythmia by providing sensing and pacing in the right ventricle; various atrioventricular conduction abnormalities by providing sensing and pacing in the right ventricle and/or right atrium. CRT-D devices sense cardiac activity and provide pacing to resynchronize the right and left ventricles. The myMerlinPulseTM mobile application is intended for use by people who have an Abbott Medical implanted heart device and access to a mobile device. The app provides remote monitoring capability of the implanted heart device by transmitting information from the patient's implanted heart device to the patient's healthcare provider. Indications: The devices are indicated in patients who have already survived a cardiac arrest or are at a high risk of Sudden Cardiac Death (SCD) due to VT (ventricular tachycardia) or VF (ventricular fibrillation). Cardiac Resynchronization Therapy (CRT) devices are indicated for reduction of symptoms in patients who have congestive heart failure, a reduced left ventricular ejection fraction (LVEF) and a prolonged QRS duration. CRT-D devices are indicated in patients who meet the CRT indications and have already survived a cardiac arrest or are at a high risk of Sudden Cardiac Death (SCD) due to VT (ventricular tachycardia) or VF (ventricular fibrillation). The device is most commonly implanted within a device pocket in the pectoral region. The myMerlinPulse mobile application is indicated for use by patients with supported Abbott Medical implanted heart devices. Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction. The myMerlinPulse mobile application is contraindicated for use with any implanted medical device other than supported Abbott Medical implanted heart devices. Adverse Events: Possible adverse events associated with the implantation of the pulse generator system include the following: Arrhythmia (for example, accelerated or induced), Bradycardia, Cardiac or venous perforation, Cardiac tamponade, Cardiogenic shock, Death, Discomfort, Embolism, Endocarditis, Erosion, Exacerbation of heart failure, Excessive fibrotic tissue growth, Extracardiac stimulation (phrenic nerve, diaphragm, pectoral muscle), Extrusion, Fluid accumulation within the device pocket, Formation of hematomas, cysts, or seromas, Heart block, Hemorrhage, Hemothorax, Hypersensitivity, including local tissue reaction or allergic reaction, Infection, Keloid formation, Myocardial damage, Nerve damage, Occlusion/Thrombus, Pericardial effusion, Pericarditis, Pneumothorax, Pulmonary edema, Syncope, Thrombosis, Valve damage. Complications reported with direct subclavian venipuncture include pneumothorax, hemothorax, laceration of the subclavian artery, arteriovenous fistula, neural damage, thoracic duct injury, cannulation of other vessels, massive hemorrhage and rarely, death. Among the psychological effects of device implantation are imagined pulsing, depression, dependency, fear of premature battery depletion, device malfunction, inappropriate pulsing, shocking while conscious or losing pulse capability. Possible adverse device effects include complications due to the following: Abnormal battery depletion, Conductor fracture, Device-programmer communication failure, Elevated or rise in defibrillation/cardioversion threshold, Inability to defibrillate or pace, Inability to interrogate or program due to programmer or device malfunction, Incomplete lead connection with pulse generator, Inhibited therapy including defibrillation and pacing, Inappropriate therapy (for example, shocks and antitachycardia pacing [ATP] where applicable, pacing), Interruption of function due to electrical or magnetic interference, Intolerance to high rate pacing (for example dyspnea or discomfort), Lead abrasion, Lead fracture, Lead insulation damage, Lead migration or lead dislodgement, Loss of device functionality due to component failure, Pulse generator migration, Rise in DFT threshold, Rise in pacing threshold and exit block, Shunting of energy from defibrillation paddles, System failure due to ionizing radiation. Additionally, potential adverse events associated with the implantation of a coronary venous lead system include the following: Allergic reaction to contrast media, Breakage or failure of implant instruments, Prolonged exposure to fluoroscopic radiation, Renal failure from contrast media used to visualize coronary veins. No potential adverse events have been identified with use of the myMerlinPulseTM mobile application. Abbott 15900 Valley View Court, Sylmar, CA 91342 Tel: +1 818 362 6822 Cardiovascular.Abbott TM Indicates a trademark of the Abbott group of companies. Indicates a third party trademark, which is property of its respective owner. © 2024 Abbott. All Rights Reserved. MAT-2408762 v2.0 | Item approved for U.S. only.Veeva Vault Veeva Vault